SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (22287)6/16/1998 9:06:00 AM
From: Hippieslayer  Respond to of 32384
 
EVen better if it works on psoriasis. Acne and psoriasis. Now that's a winning combo.



To: Sleepman who wrote (22287)6/16/1998 9:08:00 AM
From: Henry Niman  Respond to of 32384
 
Dan, For some reason, LGND has pursued oral treatments for psoriasis. The Panretin Phase II trial has been completed and the Phase II Targretin trial is on going. When completed, LGND will decide on which oral approach will be used to move to Phase III for treating psoriasis.

On the topical front, I believe that small trials for basal and squamous cell skin cancers are being targeted for Panretin and/or Targretin gels.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News